The company's documented regulatory footprint in the records reviewed centers on blood collection hardware. A premarket notification received March 16, 2026 and decided October 21, 2026 covers the Sol-Guard™ Safety Pull Button Collection Set and the Sol-Guard™ XtraThin Safety Pull-Button Blood Collection Set, classified under 21 CFR 862.1675 as a blood specimen collection device in Class II with product code JKA. The decision was Substantially Equivalent, recorded with a special clearance type and a summary statement. The applicant address on that filing is 311 S. Wacker Dr., Suite 4100, Chicago, Illinois, which is a filing address rather than a confirmed headquarters. [1][2]
Documented product line and prior clearance
An earlier FDA record for the Sol-Guard™ XtraThin Safety Pull-Button Blood Collection Set, K250907, was dated April 30, 2025 and addressed to Mike Xie as Vice President of QA/RA. That letter lists regulation number 21 CFR 862.1675, regulatory Class II, and product codes JKA and FPA, and states that the device was found substantially equivalent. The same record describes use for short-term infusion of intravenous fluids of up to two hours and for blood collection procedures in connection with a luer adapter available in a standalone version. [6]
The 2026 clearance adds a second named set, the Sol-Guard™ Safety Pull Button Collection Set, alongside the XtraThin Safety Pull-Button set. Both are described in the FDA record under the blood collection device regulation and the JKA product code, with the advisory committee listed as Clinical Chemistry. [1]
Filing record as a snapshot
The linked filing collection contains one 510(k) record, K260857, and its decision count shows one Substantially Equivalent determination. The smaller record sample likewise contains that single entry with the same decision. These counts describe the linked filings at the time of retrieval and are not measures of total company sales, total portfolio breadth or safety performance. [1]
No recall records appear in the linked collection, and no other pathway records are present. Absence of such records in this snapshot does not establish that none exist elsewhere. [1]
Company description and brand scope
Sol-Millennium's own published catalog describes a vertically integrated medical supply company with locations across the globe and states that it is one of the world's largest manufacturers of needles and syringes. The same catalog states that its technology reduces needlestick injuries and saves on medication expenses. Those are the manufacturer's characterizations, published in its documentation, not independently verified findings. [4][5]
The company website describes Sol-Millennium Medical Group as a global healthcare company engaged in design, manufacture and distribution of medical devices and personal protective equipment, and lists market segments including Diabetes Care, Medication Delivery, Blood Collection & Diagnostics, Advanced Wound Care, Vascular Access & Infusion Therapy, Veterinary Products and PPE & Accessories. The site gives a global main office address at 311 S Wacker Dr, Suite 4100, Chicago, Illinois. The relationship between the Group brand and the FDA applicant entity is not established in these records beyond the shared name and address. [8]
The 2026 blood collection catalog lists product categories spanning Diabetes Care, Medication Delivery, Vascular Access & Infusion Therapy, Blood Collection & Diagnostics, Veterinary Products, Advanced Wound Care and Personal Protective equipment, and identifies the document as a USA catalog published by Sol-Millennium Medical Inc. [3]
What remains unverified
Ownership structure, parent-subsidiary relationships, customer base, certifications, commercial availability of the newly cleared sets and any clinical performance data are not established by the records reviewed. The FDA filing address and the website office address match, but neither record confirms a manufacturing site or corporate parent. [1][8]
